Hepatitis A is a viral liver disease caused by Hepatovirus A. Many cases show no symptoms, especially in children. Symptoms appear 2-6 weeks after infection, lasting up to 8 weeks. Common symptoms include fever, nausea, jaundice, and abdominal pain
Hepatitis is liver inflammation caused by various infectious and noninfectious factors. Symptoms include nausea, vomiting, fever, fatigue, and sometimes jaundice. Fulminant hepatitis can lead to 90% mortality with rapid liver failure
HAV is common in resource-limited countries and preventable through vaccination. Since 1995, US HAV infection rate has declined by 95%. HAV infection is usually self-limited with supportive care. Full recovery occurs within 3 months in 85% of patients
FDA began implementing reorganization on October 1, 2024. HAVRIX is manufactured by GlaxoSmithKline Biologicals. Approved for use in persons 12 months and older. Primary immunization should be given 2 weeks before HAV exposure. Approval letters issued in 2018, 2021, and 2023
Vaccination should be part of comprehensive hepatitis prevention plan. WHO recommends vaccination for ages ≥12 months if disease trends change. Two-dose schedule starts from age ≥12 months. Large-scale vaccination not recommended in highly endemic countries. Early childhood vaccination recommended in improving socioeconomic status countries
Hepatitis A is liver inflammation caused by HAV virus. Spread through contaminated food/water and person-to-person contact. Incubation period is 14-28 days. Most children (90%) infected before age 10 without symptoms